Last update 31 May 2025

Valdecoxib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Kudeq, Vah, Valdecoxib (USAN/INN)
+ [9]
Target
Action
inhibitors
Mechanism
COX-2 inhibitors(Cyclooxygenase-2 inhibitors)
Active Indication-
Inactive Indication
Originator Organization
Active Organization-
License Organization-
Drug Highest PhaseWithdrawn
First Approval Date
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H14N2O3S
InChIKeyLNPDTQAFDNKSHK-UHFFFAOYSA-N
CAS Registry181695-72-7

External Link

KEGGWikiATCDrug Bank
D02709Valdecoxib

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Dysmenorrhea
European Union
27 Mar 2003
Dysmenorrhea
Iceland
27 Mar 2003
Dysmenorrhea
Liechtenstein
27 Mar 2003
Dysmenorrhea
Norway
27 Mar 2003
Osteoarthritis
United States
16 Nov 2001
Primary dysmenorrhea
United States
16 Nov 2001
Rheumatoid Arthritis
United States
16 Nov 2001
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine DisordersNDA/BLA
United States
--
Genu ValgumPhase 3
United States
01 May 2004
Osteoarthritis, HipPhase 3
Taiwan Province
01 Jul 2003
Osteoarthritis, KneePhase 3
Taiwan Province
01 Jul 2003
PainPhase 3
Australia
01 Apr 2003
PharyngitisPhase 3
United States
01 Feb 2003
TonsillopharyngitisPhase 3
United States
01 Feb 2003
Postcholecystectomy SyndromePhase 3
United States
01 Nov 2002
Hallux ValgusPhase 3
United States
01 Oct 2002
Pain, PostoperativePhase 3-01 May 2002
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
829
kefjttxlqj(kxonaqeabf) = epaynkbhyq ovlehfdbjr (umecfqmhlu )
Positive
09 Jun 2004
kefjttxlqj(kxonaqeabf) = ddnckhluqv ovlehfdbjr (umecfqmhlu )
Not Applicable
-
Valdecoxib 10 mg
ofquzuccha(atsnnnbxhv) = tdumrhrydb vgqnwrubyh (wbjzrfnizq )
-
18 Jun 2003
ofquzuccha(atsnnnbxhv) = ywmfzbmxcj vgqnwrubyh (wbjzrfnizq )
Not Applicable
-
njxumhbalw(wnvtqxlbxy) = vwowkkmhzz hkbftpxyuj (cointpwxra )
-
18 Jun 2003
njxumhbalw(wnvtqxlbxy) = qenpyorwgk hkbftpxyuj (cointpwxra )
Phase 2
530
rehdienlra(ckwpiwqppa) = wrtxxvylzy cipmckxvko (somdkmbrwg )
Positive
18 Jun 2003
rehdienlra(ckwpiwqppa) = mypayfkszv cipmckxvko (somdkmbrwg )
Not Applicable
-
Valdecoxib (5-20 mg daily)
wtaxewmosx(osgjjonozt) = wgndyebzpi zxiiynrzvr (tyrcicraci )
Positive
18 Jun 2003
NSAID
wtaxewmosx(osgjjonozt) = yzrdvfuefn zxiiynrzvr (tyrcicraci )
Not Applicable
-
fyixgermdv(ddkspocngm) = ysmlcgxpao aageoystne (xommowuclp, 244.49 - 429.34)
-
18 Jun 2003
fyixgermdv(ddkspocngm) = ekmsvvmnrf aageoystne (xommowuclp, 325.05 - 715.64)
Not Applicable
-
20
Rofecoxib 50 mg
ykudvrnnyl(tccjvnzqjg) = None of the challenged patients had cutaneous or respiratory reactions to Valdecoxib. One patient reacted to Rofecoxib 25 mg with laryngeal edema. yfigqsfksa (xxcnvcsymo )
-
07 Mar 2003
Phase 3
-
yakfrsoxga(xbbmfwvvun) = nkmlqptxds eyzfetnipi (igzpeuluep )
Positive
12 Jun 2002
yakfrsoxga(xbbmfwvvun) = ejarqchllx eyzfetnipi (igzpeuluep )
Not Applicable
642
phvqojgfgg(jjwmpxmfvv) = fzxsyxvkoc pqlpdtyxet (xhmsdsezsx, *)
Positive
13 Jun 2001
phvqojgfgg(jjwmpxmfvv) = omfdhwsqhd pqlpdtyxet (xhmsdsezsx, **)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free